Annual report pursuant to Section 13 and 15(d)

11. Commitments and Contingencies (Details Narrative)

v2.4.0.6
11. Commitments and Contingencies (Details Narrative) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Rental expense $ 392 $ 431
Potential Severance of Key Executives 1,918  
Aggregated Annual Salaries of Key Executives 1,360  
Revenue related to Vetericyn, Inc. and Innovacyn, Inc. agreements 3,906 3,367
Accounts receivable 1,707 2,151
Transaction costs 125 217
Innovacyn
   
Accounts receivable 264 290
More Pharma
   
Accounts receivable 580  
More Pharma
   
Transaction costs $ 39